LRRC8A and cancer: Studies have shown that downregulation of the SWELL1 subunit correlates with cancer cell resistance to cisplatin (Sørensen et al., 2016), suggesting that VRAC may be a promising target for overcoming cancer cell resistance in cancer therapy.